Melanoma caught early is one of the most curable cancers, with five-year survival above 99 percent for the thinnest tumors. Once it spreads to lymph nodes or distant organs, the picture changes dramatically, though modern immunotherapy has rewritten what “advanced melanoma” means for long-term survival. The gap between best-case and worst-case outcomes is wider in melanoma than in almost any other solid tumor, and the stage at diagnosis is the single biggest factor determining which side of that gap you land on.
How Staging Shapes the Prognosis
Melanoma staging under the current system (the eighth edition of the AJCC Cancer Staging Manual) revolves around three things: how deep the primary tumor has grown into the skin, whether it has reached nearby lymph nodes, and whether it has spread to distant sites. Tumor thickness, measured in millimeters, is the most powerful predictor of outcome for localized disease. The key thickness thresholds are 1.0 mm, 2.0 mm, and 4.0 mm, with survival dropping at each step up. Whether the surface of the tumor is ulcerated also matters: ulceration consistently predicts worse outcomes at every thickness level.1PubMed Central. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
One change worth knowing: the current staging system revised how the thinnest melanomas are classified. Tumors under 0.8 mm without ulceration are now T1a, while those 0.8 to 1.0 mm (with or without ulceration) or under 0.8 mm with ulceration are T1b. The cell division rate (mitotic rate), which used to be a staging criterion, was dropped from the formal T-category definitions, though doctors still record it because it remains a meaningful prognostic signal.2PubMed Central. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Early-Stage Melanoma Is Highly Curable
For stage I melanoma, where the tumor is thin and confined to the skin with no evidence of spread, surgical removal alone is curative for the vast majority of patients. Five-year survival rates in this group exceed 95 percent and approach 99 percent for the thinnest, non-ulcerated lesions. These patients generally need no chemotherapy, no immunotherapy, and no radiation. The treatment is a wide local excision with appropriate margins, and for most people that is the end of it.
The thickness of the tumor at diagnosis is what determines whether “early stage” truly means “low risk.” A melanoma measuring 0.5 mm is a fundamentally different disease from one measuring 3.5 mm, even though both might be localized to the skin at the time of surgery. This is why dermatologists emphasize catching melanoma while it is still thin. A delay of even a few months can allow a rapidly growing tumor to cross a thickness threshold that changes the entire treatment conversation.
When Localized Melanoma Is Deceptively Dangerous
Stage IIB and IIC melanomas have not yet reached lymph nodes by definition, but they are thick (greater than 2.0 mm for IIB, greater than 4.0 mm for IIC) or ulcerated, and their recurrence rates can rival or even exceed those of some stage III cancers. In one real-world study, stage IIC melanoma had a recurrence rate of about 52 percent, compared with 25 percent for stage IIIA and 31 percent for stage IIIB. In that same analysis, stage IIC was the only substage independently associated with worse recurrence-free survival compared to stage IIB, while stages IIIA and IIIB were not statistically different from IIB.3PubMed Central. Clinicopathological Predictors of Recurrence in Resected Stage IIB-IIIB Melanoma: The Prognostic Impact of Stage IIC in a Real-World Cohort
This counterintuitive finding, where a nominally “earlier” stage can behave more aggressively than a nominally “later” one, led to a major shift in treatment. Pembrolizumab became the first immunotherapy drug approved by the FDA for adjuvant treatment of completely resected stage IIB and IIC melanoma. In the KEYNOTE-716 trial, three-year recurrence-free survival was about 76 percent with pembrolizumab versus 63 percent with placebo for stage IIB, and about 81 percent versus 68 percent for stage IIC.4PubMed Central. Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions Nivolumab was later approved for the same indication, with its trial showing an even larger relative reduction in recurrence risk.
Still, the decision to start immunotherapy after surgery for stage II disease is not automatic. The absolute benefit is modest, and concerns exist about severe immune-related side effects, including permanent endocrine damage like thyroid dysfunction or adrenal insufficiency.5European Journal of Cancer. Adjuvant therapy for stage II melanoma: the need for further studies For a patient whose melanoma is already out, the trade-off between reducing recurrence risk and living with long-term treatment side effects is genuinely difficult and depends on individual circumstances.
Stage III and Regional Spread
When melanoma reaches nearby lymph nodes or produces satellite or in-transit metastases in the surrounding skin, it is classified as stage III. This is a broad category with four subgroups (IIIA through IIID), and outcomes within it vary widely. Stage IIIA, with microscopic involvement of a single node, carries a much better prognosis than stage IIID, with bulky nodal disease and an ulcerated primary.
A nationwide Swedish registry study comparing outcomes before and after the introduction of adjuvant immunotherapy for stage III melanoma found five-year overall survival of about 67 percent in the pre-immunotherapy era and about 70 percent in the post-immunotherapy era. While roughly three-quarters of patients in the newer cohort received adjuvant treatment (mostly PD-1 inhibitors), no statistically significant difference in overall or melanoma-specific survival was detected between the two time periods.6PubMed. Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study That might seem surprising given the recurrence-free survival improvements seen in clinical trials, and it highlights an important distinction: keeping cancer from coming back (recurrence-free survival) and keeping people alive (overall survival) are not the same measure. Patients who recur after surgery alone often receive effective immunotherapy at that point, potentially catching up in overall survival.
One of the most promising developments for resectable stage III disease is neoadjuvant immunotherapy, meaning treatment given before surgery rather than after. In a Swedish real-world study, about 42 percent of patients who received neoadjuvant immunotherapy achieved a major pathological response, and those responders had a 12-month recurrence-free survival rate of 94 percent.7PubMed. Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL) Combination immunotherapy regimens tend to produce higher pathological response rates than single-agent therapy, though they also carry more side effects.8PubMed Central. The Role of Neoadjuvant Immunotherapy in the Management of High-Risk Stage III Resectable Melanoma: A Literature Review The pathological response, what the tumor looks like under the microscope after treatment, is increasingly viewed as a strong early indicator of long-term outcomes.9PubMed. Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Stage IV and the Immunotherapy Transformation
Before 2011, metastatic melanoma was essentially a death sentence for most patients. Median survival hovered around eight months, and barely one in seven patients was alive at five years. The arrival of checkpoint inhibitors and targeted therapies has fundamentally changed that. A large population-based study found that for stage IV disease, median overall survival doubled from about 8 months to about 15 months, and five-year overall survival rose from 14 percent to 31 percent across the immunotherapy era.10PubMed. Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era: Persistent Racial and Socioeconomic Disparities
The most striking long-term data come from the CheckMate 067 trial, which followed patients with advanced melanoma for a minimum of ten years. Median overall survival with the combination of nivolumab plus ipilimumab was about 72 months, compared with roughly 37 months for nivolumab alone and 20 months for ipilimumab alone. Perhaps the most remarkable finding: among patients who were alive and progression-free at the three-year mark, ten-year melanoma-specific survival was 96 percent with the combination regimen and 97 percent with nivolumab alone.11PubMed Central. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma In other words, patients who responded well and remained disease-free for three years were essentially cured, with a survival curve that flattened out into near-normal life expectancy. That is a category of outcome that was unthinkable fifteen years ago.
For melanomas driven by a BRAF mutation, which accounts for roughly 40 to 50 percent of cutaneous melanomas, targeted therapy with BRAF and MEK inhibitor combinations is another option. When patients whose disease progressed after an initial round of targeted therapy were rechallenged with the same drug class after a treatment-free interval, a pooled analysis found an overall response rate of about 34 percent and a disease control rate of about 65 percent. Patients who had a drug-free interval of six months or more had a higher disease control rate than those with a shorter break.12PubMed Central. Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis Targeted therapy tends to produce fast responses but shorter durability compared to immunotherapy, so the sequencing and combination of these approaches is an active area of clinical research.
Melanoma Subtypes That Break the Pattern
The survival numbers most people encounter when researching melanoma apply primarily to cutaneous melanoma, the type that arises on sun-exposed skin. Several rarer subtypes behave differently and respond less well to current treatments.
Mucosal melanoma, which arises in the lining of the mouth, nose, sinuses, genitals, or gastrointestinal tract, carries a worse prognosis. Response rates to anti-PD-1 immunotherapy in mucosal melanoma range from essentially zero to about 23 percent in various studies, compared to roughly 30 to 40 percent for cutaneous melanoma. In one retrospective analysis, patients with mucosal melanoma treated with checkpoint inhibitors had a median overall survival of about 20 months, with a median progression-free survival of just three months.13The Oncologist. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective These tumors have a different mutational landscape, with KIT mutations more common and the kind of high mutation burden that predicts immunotherapy response less frequent.14PubMed Central. Multidisciplinary approach and treatment of acral and mucosal melanoma
Acral melanoma, which occurs on palms, soles, and under nails, shares some of these molecular features. Response rates to anti-PD-1 therapy are lower than for non-acral cutaneous melanoma, and median survival is shorter. Acral melanoma also tends to be diagnosed at a later stage because people are less likely to check these areas for skin changes and because the presentation on darker skin can be subtle.
Uveal melanoma, arising in the eye, is genetically distinct from all skin melanomas. Despite effective local treatment of the primary tumor, nearly half of patients eventually develop distant metastases, predominantly in the liver. Once liver metastases appear, median survival is roughly one year, with a two-year survival of only about 8 percent.15PubMed Central. Management of liver metastases from uveal melanoma Uveal melanoma has historically responded poorly to the checkpoint immunotherapies that transformed cutaneous melanoma, though a newer targeted therapy (tebentafusp) has shown a modest survival benefit for a specific genetic subtype.
Recurrence Can Show Up Years Later
Even after successful treatment, melanoma has an unusually long tail of recurrence risk. While most recurrences happen within the first five years, a substantial fraction do not. One study with long-term follow-up found that only about 82 percent of recurrences occurred in the first five years, and 91 percent within the first seven years, with some emerging beyond the ten-year mark.16PubMed Central. Patterns of Recurrence of Cutaneous Melanoma: A Literature Review In another series, about 4 percent of recurrences were classified as late, with five patients relapsing after a decade. Most of those late recurrences came from thin, non-ulcerated primary tumors, the kind that would have been considered low-risk at the time of initial treatment.17Journal of Clinical and Aesthetic Dermatology. Temporal Recurrence of Cutaneous Melanoma: Analysis of a Case Series
This pattern is why melanoma survivors are typically followed with clinical exams for years, sometimes indefinitely. The search for blood-based markers that could flag recurrence earlier is intense. Circulating tumor DNA, fragments of tumor-derived genetic material detectable in blood draws, has shown promise: low or undetectable levels before treatment are associated with longer progression-free and overall survival.18PubMed Central. The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment As these tools mature, they could eventually allow doctors to tailor follow-up intensity to actual molecular risk rather than stage alone.
Who Gets Left Behind in Survival Gains
The survival improvements in melanoma have not been shared equally. Black patients in the United States have consistently worse melanoma outcomes than white patients, and the reasons extend well beyond biology. Black patients are more likely to be diagnosed at later stages, experience longer times from diagnosis to surgery, and have a higher proportion of acral lentiginous melanoma, a subtype associated with greater tumor thickness at presentation.19PubMed Central. Racial Differences in the Prognosis and Survival of Cutaneous Melanoma From 1990 to 2020 in North America: A Systematic Review and Meta-Analysis In one large study, Black patients had roughly three times the hazard of death from stage I melanoma compared to white patients.20PubMed. Racial disparities in melanoma survival
When researchers looked more carefully, controlling for access to care through an equal-access healthcare system, racial differences in survival largely disappeared. Socioeconomic status turned out to be a stronger predictor of melanoma-specific mortality than race itself. In one analysis, the poorest patients in an open-insurance setting had a 70 percent higher risk of dying from melanoma compared to the wealthiest, while the same disparity vanished within an integrated healthcare system where everyone had equal access.21PubMed. Disparities in melanoma-specific mortality by race/ethnicity, socioeconomic status, and health care systems The implication is clear: much of what looks like a biological difference in melanoma survival is actually a healthcare access problem.
The Gut Microbiome and Treatment Response
One of the more unexpected findings in melanoma research over the past several years is the link between gut bacteria and immunotherapy response. In a study of patients receiving anti-PD-1 therapy, those who responded to treatment had significantly greater diversity in their gut microbiome and a higher abundance of certain bacterial families compared to non-responders. When stool samples from responding patients were transplanted into germ-free mice, those mice showed enhanced anti-tumor immunity.22PubMed Central. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Differences in gut microbial composition may also influence whether patients develop immune-related side effects from checkpoint inhibitors.23PubMed. Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity Research into how diet and supplements affect this relationship is still early. One study found that dietary fiber intake was associated with better immunotherapy responses, while, counterintuitively, probiotic supplement use was linked to reduced microbial diversity and potentially worse outcomes.24PubMed Central. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response This is a rapidly evolving area where firm clinical recommendations are premature, but it illustrates how much the understanding of melanoma treatment is expanding beyond the tumor itself.
Second Cancers After Melanoma Survival
Surviving melanoma does not end the cancer story for a meaningful number of patients. A large study found that about 12 percent of melanoma survivors developed one or more subsequent primary cancers. The overall risk of a new cancer was 28 percent higher than in the general population, and the risk of developing a second primary melanoma was roughly nine times higher, an elevation that persisted for more than 20 years after the original diagnosis. Women who had head and neck melanoma and patients diagnosed before age 30 had the highest risk of a subsequent melanoma.25PubMed Central. Increased risk of second primary cancers after a diagnosis of melanoma
For patients who received radiotherapy as part of their melanoma treatment, the risk of second primary cancers was further elevated. In a population-based cohort, second primary cancers occurred in about 8 percent of irradiated patients versus 5 percent of those who did not receive radiation. The highest relative risks were for second melanomas, soft tissue sarcomas, and blood cancers, with the greatest excess risk appearing in the 10-to-14-year window after radiation.26PubMed. Risk of second primary cancers among melanoma survivors following radiotherapy: A population-based cohort study Lifelong skin surveillance is standard for melanoma survivors, both for recurrence of the original cancer and for new primary melanomas that arise independently.